Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2021-04-30 Proxy Solicitation & In…
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2021-04-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text mentions an event on April 26, 2021, specifically a press release about the FDA removing a clinical hold on a gene therapy program. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3298 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of quarterly or annual financial results, management discussion, or audit information. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2021-04-26 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a Cooperation Agreement entered into by the company and certain entities, as well as a settlement of a legal dispute. There are no financial statements or detailed financial performance data presented, nor is this an earnings release or annual/interim report. The document primarily announces a material definitive agreement and other significant events. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2021-04-22 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-22 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to provide shareholders with information to vote on matters at the Annual General Meeting (AGM). It includes details about the meeting date, agenda items, voting instructions, and references to the Annual Report on Form 10-K but does not contain the full annual report itself. The document is clearly a proxy solicitation material intended to inform and solicit votes from shareholders for the AGM. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is not a brief announcement or a full annual report but a detailed proxy statement.
2021-04-20 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.